The Osaka Metropolitan University study explored the relationship between autoimmune gastritis (AIG) and the development of gastric neuroendocrine tumors (NETs), focusing on the role of gut microbiota and metabolic changes. AIG is a chronic autoimmune disorder where the immune system attacks the stomach lining, leading to tissue damage and prolonged inflammation.
The Osaka Metropolitan University study explored the relationship between autoimmune gastritis (AIG) and the development of gastric neuroendocrine tumors (NETs), focusing on the role of gut microbiota and metabolic changes. AIG is a chronic autoimmune disorder where the immune system attacks the stomach lining, leading to tissue damage and prolonged inflammation. This inflammation is a known risk factor for NETs, tumors originating from hormone-producing cells.
The study compared stomach tissue and gut microbiota profiles of AIG patients with and without NETs. AIG patients showed reduced α-diversity in gut bacteria, an indicator of poor gastric health. Distinct microbial profiles were observed between NET-positive and NET-negative groups. Harmful bacteria, such as *Haemophilus parainfluenzae* and Fusobacterium species (*F. periodonticum* and *F. nucleatum*), were elevated in NET-positive patients, while protective microbes like lactic acid bacteria and *Streptococcus salivarius* were diminished. This imbalance created a pro-inflammatory environment conducive to tumor formation.
Metabolomic analysis revealed metabolic reprogramming in AIG patients, with a shift away from normal glycolysis and TCA cycles to alternative energy pathways. This disruption affected energy balance, inflammation control, and tissue repair mechanisms. The sequence of events suggested metabolic dysfunction occurred first, fostering conditions for harmful bacterial overgrowth and subsequent tumor development.
The study identified microbial and metabolic biomarkers that could predict NET risk, offering potential for early diagnosis and preventive strategies. These findings underscore the combined impact of immune damage, altered metabolism, and microbiome imbalance in AIG-related cancer progression, paving the way for innovative diagnostic and therapeutic approaches.
Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...
Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...
Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...
Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...
Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...
Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.